American Association for Cancer Research Annual Meeting (AACR)

Videos

Kim detailed the specifics of his research from the American Association for Cancer Research Annual Meeting 2021 focusing on novel therapies to target mutations and upstream or downstream pathways.

Michael Kim, MD, on Genetics and the Need for Novel Therapies in Pancreatic Cancer

Marron detailed the research process for a phase 1 trial of PGV-001 presented virtually at the American Association for Cancer Research Annual Meeting 2021.

Thomas Marron, MD, PhD, on Research Design for the Neoantigen Peptide Vaccine, PGV-001

Articles

Twenty percent of patients with resectable hepatocellular carcinoma experienced significant tumor necrosis when treated with neoadjuvant cemiplimab-rwlc, according to data from a phase 2a open label.

Complete Pathological Responses Seen for Resectable HCC Treated With Neoadjuvant Cemiplimab

Patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior treatment experienced a clinically meaningful efficacy when treated with D-0316.

Clinically Significant Improvement Observed With D-0316 for Subset of Patients with T790M+ and EGFR+ NSCLC

A promising objective response rate and a tolerable safety profile were observed with telisotuzumab vedotin monotherapy to treat patients with previously treated c-Met–positive advanced non–small cell lung cancer.

Strong Efficacy and Safety Data Observed With Telisotuzumab Vedotin for c-Met+ NSCLC

Patients with germline and/or homozygous tumor DNA damage response alterations among male patients with heavily pretreated metastatic castration-resistant prostate cancer were most likely to respond to treatment with the PARP inhibitor talazoparib.

Talazoparib Most Likely to Inhibit Response in Men With Heavily Pretreated mCRPC

In a phase 1 study of the innate cell engager AFM13, all 4 patients with CD30-positive, relapsed/refractory Hodgkin lymphoma treated with the therapy achieved at least a partial response.

Responses Observed in Entire Cohort of Patients With R/R CD30+ Hodgkin Lymphoma Receiving AFM13

The majority of independently adjudicated interstitial lung disease cases associated with the antibody-drug conjugate were low grade and occurred within the first 12 months of treatment.

Pooled Analysis Supports Benefit/Risk Profile of Trastuzumab Deruxtecan in Various Advanced Cancers

A durable clinical benefit was seen from the dual inhibition of the MAPK pathway using BRAF and MEK inhibitors dabrafenib and trametinib, respectively, to treat patients with BRAF V600E mutant low- and high-grade glioma.

Clinical Benefit Observed With Dabrafenib Plus Trametinib Combo for Glioma Subtypes

The clinical benefit rate of the neratinib plus fulvestrant combination treatment did not meet the predefined efficacy threshold, but was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer.

American Association for Cancer Research Annual Meeting (AACR) | Conference